Meds & supplements › Idelalisib
Medicine · Kinase Inhibitor
Idelalisib
Zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities. Zydelig is a…
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
Drug facts
- Used for
- Relapsed chronic lymphocytic leukemia (CLL)
- in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities. Limitations of use: Zydelig is not indicated and is not recommended for first-line treatment of any patient, including patients with CLL, small lymphocytic lymphoma (SLL), follicular lymphoma (FL), and other indolent non-Hodgkin lymphomas. ( 1, 6.1 ) Zydelig is not indicated and is not recommended
- in combination with bendamustine and rituximab, or
- Do not take if
- Zydelig is contraindicated in patients with a history of serious hypersensitivity reactions to idelalisib, including anaphylaxis, or patients with a history of toxic epidermal necrolysis with any drug.
What it is used for
Zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.
Side effects, and when to stop
The following clinically significant adverse reactions are described elsewhere in the labeling.
Who should not take it
Zydelig is contraindicated in patients with a history of serious hypersensitivity reactions to idelalisib, including anaphylaxis, or patients with a history of toxic epidermal necrolysis with any drug.
Storing it
Store between 20–30 °C (68–86 °F) with excursions permitted 15–30 °C (59–86 °F).
- Dispense only in original container.
- Do not use if seal over bottle opening is broken or missing.
Cite this page
- NLM
sofidex [Internet]. Daloreum; c2026. Idelalisib; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/idelalisib
- APA 7th
sofidex. (2026, August 3). Idelalisib. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/idelalisib
- AMA 11th
Idelalisib. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/idelalisib
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.